


REPAIR Trial Newsletter



Issue 30 September 2012

Recruitment update



Frequently Asked Questions

Question: Should patients receiving Campath (alemtuzumab) induction be excluded from the study?

Answer: Yes, these patients should be excluded from Repair as Campath works in a different way from Simulect (basiliximab), having different immunological effects which might have an effect upon outcome. Additionally, patients receiving Campath typically receive less Tacrolimus, and this could lead to bias in the study. This means that patients included in the 3C trial cannot also be included in Repair.

REPAIR trial office

Just to let you know Steve Robertson will be on holiday from 31 August until 10th September, returning to office on Tuesday 11th September.

Rosey Knight will be on holiday from 10th September returning to the office on Monday 24th September.

On Monday 10th September there will be limited office cover due to departmental retreat and only urgent queries will be dealt with.